ARQT Stock Forecast 2025-2026
Distance to ARQT Price Targets
ARQT Price Momentum
10 Quality Stocks Worth Considering Now
Researching Arcutis (ARQT) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on ARQT and similar high-potential opportunities.
Latest ARQT Stock Price Targets & Analyst Predictions
Based on our analysis of 15 Wall Street analysts, ARQT has a bullish consensus with a median price target of $19.50 (ranging from $15.00 to $29.00). The overall analyst rating is Strong Buy (8.8/10). Currently trading at $14.62, the median forecast implies a 33.4% upside. This outlook is supported by 7 Buy, 1 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Jonathan Block at Goldman Sachs, suggesting a 2.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ARQT Analyst Ratings
ARQT Price Target Range
Latest ARQT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ARQT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 11, 2025 | Jefferies | Kambiz Yazdi | Buy | Maintains | $19.00 |
| Feb 27, 2025 | Goldman Sachs | Jonathan Block | Neutral | Maintains | $15.00 |
| Feb 26, 2025 | Needham | Serge Belanger | Buy | Reiterates | $20.00 |
| Feb 26, 2025 | Mizuho | Uy Ear | Outperform | Maintains | $21.00 |
| Feb 26, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $19.00 |
| Feb 24, 2025 | Guggenheim | Seamus Fernandez | Buy | Reiterates | $0.00 |
| Feb 10, 2025 | Guggenheim | Seamus Fernandez | Buy | Reiterates | $0.00 |
| Jan 13, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $19.00 |
| Jan 7, 2025 | Mizuho | Uy Ear | Outperform | Maintains | $20.00 |
| Dec 30, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Initiates | $19.00 |
| Dec 17, 2024 | Needham | Serge Belanger | Buy | Maintains | $20.00 |
| Nov 7, 2024 | Needham | Serge Belanger | Buy | Reiterates | $18.00 |
| Aug 28, 2024 | Jefferies | Kambiz Yazdi | Buy | Initiates | $15.00 |
| Aug 15, 2024 | Needham | Serge Belanger | Buy | Reiterates | $18.00 |
| Jul 30, 2024 | Needham | Serge Belanger | Buy | Reiterates | $18.00 |
| Jul 10, 2024 | Needham | Serge Belanger | Buy | Reiterates | $18.00 |
| May 15, 2024 | Mizuho | Uy Ear | Buy | Maintains | $18.00 |
| May 15, 2024 | Needham | Serge Belanger | Buy | Maintains | $18.00 |
| Apr 12, 2024 | Needham | Serge Belanger | Buy | Reiterates | $16.00 |
| Feb 28, 2024 | Needham | Serge Belanger | Buy | Maintains | $16.00 |
Arcutis Biotherapeutics Inc. (ARQT) Competitors
The following stocks are similar to Arcutis based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Arcutis Biotherapeutics Inc. (ARQT) Financial Data
Arcutis Biotherapeutics Inc. has a market capitalization of $1.73B with a P/E ratio of -12.6x. The company generates $196.54M in trailing twelve-month revenue with a -71.3% profit margin.
Revenue growth is +427.6% quarter-over-quarter, while maintaining an operating margin of -10.7% and return on equity of -113.8%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Arcutis Biotherapeutics Inc. (ARQT) Business Model
About Arcutis Biotherapeutics Inc.
Develops innovative dermatological treatments.
Arcutis Biotherapeutics generates revenue by developing and commercializing proprietary topical treatments for various skin diseases, focusing on conditions like psoriasis and atopic dermatitis. Their business model relies on a robust pipeline of investigational drugs aimed at filling treatment gaps and enhancing patient comfort and efficacy.
The company is strategically positioned in Westlake Village, California, and aims to improve the standard of care in dermatology through advanced formulation science. Their initiatives seek to provide safer and more effective alternatives for millions suffering from dermatological disorders, marking Arcutis as a significant player in the pharmaceutical industry.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
342
CEO
Mr. Todd Franklin Watanabe M.A.
Country
United States
IPO Year
2020
Website
www.arcutis.comArcutis Biotherapeutics Inc. (ARQT) Latest News & Analysis
Arcutis Biotherapeutics (ARQT) and Benitec Biopharma (BNTC) performance details relative to their sector have been reported for this year. Further specifics were not provided.
Performance comparison indicates how Arcutis and Benitec are faring against industry peers, influencing investor sentiment and potential investment decisions based on relative strength.
Arcutis Biotherapeutics granted 27,000 restricted stock units to three new employees as part of its 2022 Inducement Plan, approved by its Compensation Committee on March 3, 2025.
The grant of restricted stock units signals Arcutis' growth and investment in talent, potentially enhancing innovation and performance, which can positively impact stock value.
ZORYVE® (roflumilast) cream shows favorable safety and tolerability in atopic dermatitis. Investigational foam form also demonstrates efficacy in scalp psoriasis. AD and psoriasis affect millions in the U.S.
Positive data for ZORYVE® in treating atopic dermatitis and psoriasis suggests strong market potential, potentially boosting the company's stock value and appealing to investors in the biotech sector.
Wall Street analysts set an average price target for Arcutis Biotherapeutics (ARQT) suggesting a 48.4% upside, supported by positive earnings estimate revisions.
The 48.4% price target upside suggests strong growth potential for Arcutis Biotherapeutics, while positive earnings revisions may boost investor confidence and drive stock performance.
Arcutis Biotherapeutics, Inc. (ARQT) has reached a key support level and surpassed its 50-day moving average, indicating a potential short-term bullish trend.
Arcutis Biotherapeutics (ARQT) showing a key support level and surpassing the 50-day moving average indicates potential short-term gains, signaling a bullish trend for traders.
Phase 1b study data for ARQ-255 in alopecia areata expected in H1 2025. Alopecia market projected at $6.92B by 2034. ZORYVE's 2024 revenue reached $166.5M, up 471% YoY.
ARQ-255's phase 1b study results could influence its market entry in a $6.92 billion industry, while ZORYVE's significant revenue growth signals strong demand and potential for future gains.
Frequently Asked Questions About ARQT Stock
What is Arcutis Biotherapeutics Inc.'s (ARQT) stock forecast for 2025?
Based on our analysis of 15 Wall Street analysts, Arcutis Biotherapeutics Inc. (ARQT) has a median price target of $19.50. The highest price target is $29.00 and the lowest is $15.00.
Is ARQT stock a good investment in 2025?
According to current analyst ratings, ARQT has 7 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $14.62. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ARQT stock?
Wall Street analysts predict ARQT stock could reach $19.50 in the next 12 months. This represents a 33.4% increase from the current price of $14.62. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Arcutis Biotherapeutics Inc.'s business model?
Arcutis Biotherapeutics generates revenue by developing and commercializing proprietary topical treatments for various skin diseases, focusing on conditions like psoriasis and atopic dermatitis. Their business model relies on a robust pipeline of investigational drugs aimed at filling treatment gaps and enhancing patient comfort and efficacy.
What is the highest forecasted price for ARQT Arcutis Biotherapeutics Inc.?
The highest price target for ARQT is $29.00 from at , which represents a 98.4% increase from the current price of $14.62.
What is the lowest forecasted price for ARQT Arcutis Biotherapeutics Inc.?
The lowest price target for ARQT is $15.00 from Jonathan Block at Goldman Sachs, which represents a 2.6% increase from the current price of $14.62.
What is the overall ARQT consensus from analysts for Arcutis Biotherapeutics Inc.?
The overall analyst consensus for ARQT is bullish. Out of 15 Wall Street analysts, 7 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $19.50.
How accurate are ARQT stock price projections?
Stock price projections, including those for Arcutis Biotherapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
